Oral manifestations of adverse drug reactions: Guidelines

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 6, 2008, Pages 681-691

  Femiano, F ^a,b   Lanza, A ^a   Buonaiuto, C ^a   Gombos, F ^a   Rullo, R ^a   Festa, V ^a   Cirillo, N ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE   (Italy)

Author keywords

Adverse drug effects; Drug reactions; Oral mucosal reactions; Oral reactions; Side effects

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CONTRACEPTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ELLIPTINIUM; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENICILLAMINE; PHENOTHIAZINE; PHENYTOIN; PROTEINASE INHIBITOR; RETINOID; SULFONAMIDE; TRAMADOL; UNINDEXED DRUG;

ADVERSE DRUG REACTION; ANGIONEUROTIC EDEMA; ARTICLE; BONE NECROSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; ERYTHEMA MULTIFORME; GINGIVA BLEEDING; GINGIVA DISEASE; HUMAN; LICHENOID ERUPTION; MOUTH DISEASE; MOUTH LESION; MOUTH ULCER; MUCOSAL PIGMENTATION; ORAL BURNING; PEMPHIGUS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TARDIVE DYSKINESIA; TASTE DISORDER; XEROSTOMIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AKATHISIA, DRUG-INDUCED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; ERYTHEMA MULTIFORME; HUMANS; JAW DISEASES; MOUTH DISEASES; OSTEONECROSIS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 43849083246     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02637.x     Document Type: Article

References (65)

1. Lacoste-Roussillon C, Pouyanne P, Haramburu F, Miremont G, Begaud B. Incidence of serious adverse drug reactions in general practice: A prospective study. Clin Pharmacol Ther 2001; 69: 458-462.
2. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259.
3. Abdollahi M, Radfar MA. Review of drug-induced oral reactions. J Contemp Dent Pract 2003; 4: 10-31.
4. Aronson JK, Ferner RE. Joining the DoTS: New approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-1225.
5. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005; 152: 968-974.
6. Vervloet D, Durham S. Adverse reactions to drugs. BMJ 1998; 316: 1511-1514.
7. Guggenheimer J. Oral manifestations of drug therapy. Dent Clin North Am 2002; 46: 857-868.
8. DeRossi SS, Hersh EV. A review of adverse oral reactions to systemic medications. Gen Dent 2006; 54: 131-138.
9. Nigen S, Knowles SR, Shear NH. Drug eruptions: Approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003; 2: 278-299.
10. Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics 2001; 108: 485-492.
11. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 2001; 286: 2270-2279.
12. Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 2002; 34: 83-98.
13. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-1294.
14. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-850.
15. Bjornsson TD, Wagner JA, Donahue SR et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003; 13: 943-967.
16. Thomson WM, Chalmers JM, Spencer AJ, Slade GD. Medication and dry mouth: findings from a cohort study of older people. J Public Health Dentistry 2000; 60: 12-20.
17. Scully C. Drug effects on salivary glands; dry mouth. Oral Dis 2003; 9: 165-176.
18. Wynn RL, Meiller TF. Drugs and dry mouth. Gen Dent 2001; 49: 10-12.
19. Torpet LA, Kragelund C, Reibel J, Nauntofte B. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Medical 2004; 15: 28-46.
20. Guggenheimer J. Oral Manifestations of drug therapy. Dent Clin N Am 2002; 46: 857-868.
21. Femiano F, Scully C, Gombos F. Idiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapy. Int J Oral Maxillofac Surg 2002; 31: 625-628.
22. Ackerman BH, Kasbekar N. Disturbances of taste and smell induced by drugs. Pharmacotherapy 1997; 17: 482-496.
23. Femiano F, Scully C, Gombos F. Linear IgA dermatosis induced by a new angiotensin-converting enzyme inhibitor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 169-173.
24. Madinier I, Berry N, Chichmanian RM. Drug-induced oral ulcerations. Ann Med Interne (Paris) 2000; 151: 248-254.
25. Scully C, Azul AM, Crighton A, Felix D, Field A, Porter S. Nicorandil can induce severe oral ulceration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 189-193.
26. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Medical 2004; 15: 221-239.
27. Gaig P, San Miguel-Moncin MM, Bartra J, Bonet A, Garcia-Ortega P. Usefulness of patch tests for diagnosing selective allergy to captopril. J Invest Allergol Clin Immunol 2001; 11: 204-206.
28. Taylor BA. Management of drug-induced gingival enlargement. Aust Prescr 2003; 26: 11-13.
29. Samarasinghe YP, Cox A, Feher MD. Calcium channel blocker induced gum hypertrophy: No class distinction. Heart 2004; 90: 16-18.
30. Vescovi P, Meleti M, Manfredi M, Bonanini M. Pathogenesis of cyclosporine induced gingival overgrowth. Minerva Stomatol 2003; 52: 219-229.
31. Fujimori Y, Maeda S, Saeki M, Morisaki I, Kamisaki Y. Inhibition by nifedipine of adherence- and activated macrophage-induced death of human gingival fibroblasts. Eur J Pharmacol 2001; 415: 95-103.
32. Das SJ, Newman HN, Olsen I. Keratinocyte growth factor receptor is up-regulated in cyclosporine-A induced gingival hyperplasia. J Dent Res 2002; 81: 683-687.
33. Shimizu Y, Kataoka M, Seto H, Kido J, Nagata T. Nifedipine induces gingival epithelial hyperplasia in rats through inhibition of apoptosis. J Periodontol 2002; 73: 861-867.
34. Tu HP, Chen YT, Shieh YS et al. Cyclosporin-induced downregulation of the expression of E-cadherin during proliferation of edentulous gingival epithelium in rats. J Periodontol 2006; 77: 832-839.
35. Katz J, Caudle RM, Bhattacharyya I, Stewart CM, Cohen DM. Receptor for advanced glycation end product (RAGE) upregulation in human gingival fibroblasts incubated with nornicotine. J Periodontol 2005; 76: 1171-1174.
36. Diederich NJ, Goetz CG. Drug-induced movement disorders. Neurol Clin 1998; 16: 125-139.
37. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psy-Chiatry 2000; 61: 39-44.
38. Tarsy D, Indorf G. Tardive tremor due to metoclopramide. Mov Disord 2002; 17: 620-621.
39. Eisen D. Disorders of pigmentation in the oral cavity. Clin Dermatol 2000; 18: 579-587.
40. Tamam L, Annagur BB. Black hairy tongue associated with olanzapine treatment: A case report. Mt Sinai J Med 2006; 73: 891-894.
41. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treat-ment. Am J Clin Dermatol 2001; 2: 253-262.
42. Abdollahi M, Radfar M. review of drug induced oral reactions. J Contemp Dent Pract 2003; 4: 10-31.
43. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Safety 2001; 24: 599-606.
44. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: Outcome after switching to a different treatment. Arch Intern Med 2004; 164: 910-913.
45. Field TS, Gurwitz JH, Avorn J et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161: 1629-1634.
46. Scully C, Challacombe SJ. Pemphigus vulgaris: Update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Medical 2002; 13: 397-408.
47. Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: Report of two cases. Int J Dermatol 2006; 45: 1471-1473.
48. Ena P, Chiarolini F, Siddi GM, Cossu A. Oral lichenoid eruption secondary to imatinib. J Dermatolog Treat 2004; 15: 253-255.
49. Robinson NA. Lichenoid tissue reactions of the oral mucosa. Singapore Dent J 2000; 23: 56-63.
50. Scoyni RM, Aiello L, Trani I et al. Drug adverse events and drop-out risk: A clinical case. Arch Gerontol Geriatr 2007; 441: 359-364.
51. Mou SS, Punaro L, Anton J, Luckett PM. Severe systemic hypersensitivity reaction to ibuprofen: A presentation of systemic lupus erythematosus. J Rheumatol 2006; 33: 171-172.
52. Kragelund C, Thomsen CE, Bardow A et al. Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes. Oral Dis 2003; 9: 177-187.
53. Cohen DM, Bhattacharyya I. Cinnamon-induced oral erythema multiforme-like sensitivity reaction. J Am Dent Assoc 2000; 131: 929-934.
54. Ayangco L, Rogers RS III X. Oral manifestations of erythema multiforme. Dermatol Clin 2002: 21: 195-205.
55. Ho LL, Brighton T. Warfarin, antiplatelet drugs and their interactions. Aust Prescr 2002; 25: 81-85.
56. Brown RS, Farquharson AA, Sam FE, Reid E. A retrospective evaluation of 56 patients with oral burning and limited clinical findings. Gen Dent 2006; 54: 267-271.
57. Femiano F, Gombos F, Esposito V, Nunziata M, Scully C. Burning mouth syndrome (BMS): Evaluation of thyroid and taste. Med Oral Patol Oral Cir Bucal 2006; 11: 22-25.
58. Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on cancer. Calcif Tissue Int 2003; 73: 315-318.
59. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83-93.
60. Babu KS, Belgi G. Management of cutaneous drug reactions. Curr Allergy Asthma Report 2002; 2: 26-33.
61. Spolarich AE. Managing the side effects of medications. J Dent Hyg 2000; 74: 57-69.
62. Puavilai S, Chunharas A, Kamtavee S, Pongwiriyapanich S. Drug eruptions: the value of oral rechallenge test and patch test. J Med Assoc Thai 2002; 85: 263-269.
63. Jacobsen PL, Chavez EM. Clinical management of the dental patient taking multiple drugs. J Contemp Dent Pract 2005; 6: 144-151.
64. Li B, Wang Z, Fang JJ, Xu CY, Chen WX. Evaluation of prognostic markers in severe drug-induced liver disease. World J Gastroenterol 2007; 13: 628-632.
65. Ozcelik O, Haytac MC. Oral challenge test for the diagnosis of gingival hypersensitivity to apple: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 317-321.